[1]扈若凡 徐少勇 沈涵 景策 贾爱华 鱼馨文 邢影 梁声茹 明洁 姬秋和.非酒精性脂肪性肝病人群细胞角蛋白18 水平与2型糖尿病发病风险[J].国际内分泌代谢杂志,2020,40(04):228-232.[doi:10.3760/cma.j.issn.1673-4157.2020.04.003]
　Hu Ruofan,Xu Shaoyong,Shen Han,et al.Cytokeratin-18 level and the risk of type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2020,40(04):228-232.[doi:10.3760/cma.j.issn.1673-4157.2020.04.003]
点击复制

非酒精性脂肪性肝病人群细胞角蛋白18 水平与2型糖尿病发病风险
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年04期
页码:
228-232
栏目:
论著
出版日期:
2020-07-20

文章信息/Info

Title:
Cytokeratin-18 level and the risk of type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease
作者:
扈若凡1 徐少勇1; 2 沈涵1; 3 景策1; 4 贾爱华1; 5 鱼馨文1 邢影1 梁声茹1 明洁1 姬秋和1
1空军军医大学附属西京医院内分泌科,西安 710032; 2湖北文理学院襄阳市中心医院内分泌科 441021; 3北京四季青医院内科 100097; 4首都医科大学附属北京同仁医院内分泌科 100176; 5榆林市第一医院内分泌科 718000
Author(s):
Hu Ruofan1;  Xu Shaoyong1; 2;  Shen Han1; 3;  Jing Ce1; 4;  Jia Aihua1; 5;  Yu Xinwen1;  Xing Ying1;  Liang Shengru1;  Ming Jie1;  Ji Qiuhe1
1Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China; 2Department of Endocrinology, Xiangyang Central Hospital of Hubei University of Arts and Science, Xiangyang 441021, China; 3Department of Internal Medicine, Beijing SijiqingHospital, Beijing 100097, China; 4Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China; 5Department of Endocrinology, The First Hospital of Yulin, Yulin 718000, China
关键词:
细胞角蛋白-18;  非酒精性脂肪性肝病;  2型糖尿病
Keywords:
Cytokeratin-18;  Non-alcoholic fatty liver disease;  Type 2 diabetes mellitus
DOI:
10.3760/cma.j.issn.1673-4157.2020.04.003
摘要:
目的 探讨血清细胞角蛋白-18(CK-18)水平与非酒精性脂肪性肝病(NAFLD)人群2型糖尿病(T2DM)的发病风险。方法 队列研究基于2007—2008年中国糖尿病和代谢紊乱调查,随访期为5年。依据超声诊断NAFLD,糖耐量试验诊断T2DM,用M30凋亡ELISA试剂盒检测血清CK-18水平。共有457例受试者被纳入作为研究人群,并分为3组。首先根据超声结果分为2组:非NAFLD组(363例)和NAFLD组(94例)、再依照CK-18水平二分位将NAFLD组分为低CK-18-NAFLD组(46例)和高CK-18-NAFLD组(48例)。采用Cox比例风险回归模型计算NAFLD人群中T2DM的发病风险,并进行多因素分析。结果 随访期间19例受试者(3.9%)发生糖尿病。非NAFLD组、低CK-18-NAFLD组和高CK-18-NAFLD组T2DM发生率分别为2.5%(9/363)、8.7%(4/46)和12.5%(6/48)。Cox比例风险回归显示,与非NAFLD组相比,低CK-18-NAFLD组和高CK-18-NAFLD组T2DM的校正后相对风险分别为3.37(95% CI:1.05～10.86,P=0.042)和4.71(95% CI:1.71～12.99,P=0.003)。结论 超声诊断的NAFLD患者CK-18水平与T2DM风险存在相关性。
Abstract:
Objective To explore the relationship between serum cytokeratin-18(CK-18)and the risk of type 2 diabetes mellitus(T2DM)in patients with non-alcoholic fatty liver disease(NAFLD).Methods The population-based cohort study was based on 2007-2008 China National Diabetes and Metabolic Disorders Survey with a follow-up of five years. NAFLD was determined by ultrasonography. T2DM was diagnosed based on oral glucose tolerance test. Serum CK-18 was measured using the M30 apoptosense ELISA kit. A total of 457 subjects were included in the study and divided into three groups.According to the ultrasonic results, they were firstly divided into two groups: non-NAFLD group(363 cases)and NAFLD group(94 cases), then NAFLD group was divided into low CK-18-NAFLD group(46 cases)and high CK-18-NAFLD group(48 cases)according to the level of CK-18. Cox proportional risk regression analysis was used to check the relationship between NAFLD and the risk of T2DM and multivariate analysis was applied.Results The incidence of T2DM was 2.5%(9/363), 8.7%(4/46), and 12.5%(6/48)in the non-NAFLD group, low-CK-18 NAFLD group, and high-CK-18 NAFLD group, respectively. Cox proportional hazard regression showed that, compared with non-NAFLD group, the adjusted relative risks of T2DM were 3.37(95% CI: 1.05-10.86, P=0.042)and 4.71(95% CI: 1.71-12.99, P=0.003), respectively, in the low-CK-18 NAFLD group and high-CK-18 NAFLD group.Conclusion The level of CK-18 in patients with NAFLD diagnosed by ultrasound may be related to the risk of T2DM.

参考文献/References:

[1] De Alwis NM, Day CP. Non-alcoholic fatty liver disease:the mist gradually clears[J].J Hepatol, 2008, 48(Suppl 1):S104-S112.DOI:10.1016/hep.2008.009.
[2] Haga Y,Kanda T,Sasaki R, et al. Nonalcoholic fatty liver disease and epatic cirrhosis:comparison with viral hepatitis-associated steatosis[J].World J Gastroenterol, 2015,21(46):12989-12995.DOI:10.3748/wjg.2015.12989.
[3] Younossi ZM,Koenig AB,Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liverdisease-meta-analytic assessment of prevalence, incidence, and outcomes[J].J Hepatol,2016,64(1):73-84.DOI: 10.1002/hep.2016.28431.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会,范建高,等.非酒精性脂肪性肝病防治指南(2018年更新版)[J].实用肝脏病杂志, 2018,21(2):30-39.DOI:10.3969/j.issn.1672-5069.2018.02.007.
[5] Nagpal SJ, Lopez R,Feldstein AE, et al. Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD [J].Liver Int, 2015,35(12):2621.DOI:10.1111/liv.2015.12862.
[6] Chang YH, Lin HC, Hwu DW, et al. Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease[J].Ann Clin Biochem,2019,56(1):141-147. DOI:10.1177/0004563218796259.
[7] Alberti KG, Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J].Diabet Med,1998,15(7):539-553.DOI:10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO; 2-S.
[8] Farrell GC, Chitturi S, Lau GK,et al. Asia-pacific working party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary[J].J Gastroenterol Hepato,2007,22(6):775-777. DOI:10.1111/j.1440-1746.2007.05002.x.
[9] Ming J, Xu S, Gao B, et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China:a five-year cohort study [J].Liver Int, 2015,35(11):2401-2407.DOI:10.1111/liv.2015.12851.
[10] Kotronen A,Laaksonen MA,Heliövaara M,et al. Fatty liver score and 15-year incidence of type 2 diabetes [J].Hepatol Int,2013,7(2):610-621.DOI:10.1007/s12072-013-9430-7.
[11] Ballestri S,Zona S,Heliövaara M, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J].J Gastroenterol Hepatol, 2016,31(5):936-944.DOI:10.1111/jgh.2016.13264.
[12] Nobili V,Mantovani A,Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease[J].J Hepatol,2019, 71(4):802-810.DOI:10.1016/j.jhep.2019.06.023.
[13] Galluzzi L1,Maiuri MC,Vitale I, et al. Cell death modalities: classification and pathophysiological implications [J].Cell Death Differ,2007,14(7):1237-1243.DOI:10.1038/sj.cdd.4402148.
[14] Feldstein AE,Canbay A,Angulo P,et al.Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis[J].Gastroenterology,2003,125(2):437-443.DOI:10.1016/s0016-5085(03)00907-7.
[15] Tsutsui M,Tanaka N,Kawakubo M, et al. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels[J].J Clin Gastroenterol, 2010,44(6):440-447.DOI:10.1097/MCG.0b013e3181bdefe2.
[16] Mandelia C,Collyer E,Mansoor S, et al. Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease [J].J Pediatr Gastroenterol Nutr,2016,63(2):181-187. DOI:10.1097/MPG.0000000000001136.
[17] Arab JP,Hernández-Rocha C,Morales C,et al.Arrese M.Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population[J].Gastroenterol Hepatol, 2017,40(6):388-394.DOI:10.1016/j.gastrohep.2017.02.009.
[18] Ming J, Xu S, Gao B,et al. Response to serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD[J].Liver Int, 2015,35(12):2622.DOI:10.1111/liv.2015.12867.

相似文献/References:

[1]曹涵,曲伸.过氧化物酶体增殖物活化受体与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
　Cao Han,Qu Shen..Peroxisome proliferator-activated receptors and non-alcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
[2]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
　Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(04):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[3]聂秀玲,李明珍,孙丽荣.高尿酸血症与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
　Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(04):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[4]张洁,邸阜生.运动防治非酒精性脂肪性肝病的机制[J].国际内分泌代谢杂志,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
　Zhang Jie,Di Fusheng..Mechanism of exercise on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2016,36(04):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
[5]张雅楠,郗光霞,杨翠萍,等.自噬在非酒精性脂肪性肝病中的变化及作用[J].国际内分泌代谢杂志,2017,37(01):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
　Zhang Yanan*,Xi Guangxia,Yang Cuiping,et al.The change and function of autophagy in nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(04):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
[6]李博,苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的 关系[J].国际内分泌代谢杂志,2017,37(03):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
　Li Bo,Su Qing..Relationship between advanced glycation end-products and its receptor in nonalcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2017,37(04):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
[7]狄红杰,刘超.饮食干预对非酒精性脂肪性肝病肠道菌群的影响[J].国际内分泌代谢杂志,2017,37(04):254.
　Di Hongjie,Liu Chao..Effects of diet interventions on gut microbiota of nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(04):254.
[8]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
　Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(04):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[9]李霞 雷涛.铁过载与代谢性疾病的关系[J].国际内分泌代谢杂志,2018,38(01):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
　Li Xia*,Lei Tao..Relationship between iron overload and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(04):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
[10]曹白鸽 董艳.母体妊娠期高脂饮食所致的炎性反应状态对子代的影响[J].国际内分泌代谢杂志,2018,38(02):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]
　Cao Baige*,Dong Yan..Effects of inflammatory state on offspring induced by maternal high-fat diet during pregnancy[J].International Journal of Endocrinology and Metabolism,2018,38(04):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]

备注/Memo

备注/Memo:
通信作者:姬秋和,Email:jqiuhe@fmmu.edu.cn
基金项目:国家重点专项(2017YFC1309803); 陕西省重大研究项目(2017ZDCXLSF0201)
Corresponding author: Ji Qiuhe, Email: jqiuhe@fmmu.edu.cn
Fund program:National Key Research and Development Project(2017YFC1309803); The Key Research and Development Program of Shanxi Province of China(2017ZDCXLSF0201)
更新日期/Last Update: 2020-07-20